RCTs | Secukinumab in moderate-to-severe hidradenitis suppurativa
3 Mar, 2023 | 13:30h | UTCSecukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials – The Lancet (link to abstract – $ for full-text)